



Purchase of AstraZeneca plc – 10 May 2019

AstraZeneca is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area, as well as investing to explore the benefits of its franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I trials, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II trials, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

This week AstraZeneca and Daiichi Sankyo Company said their phase I breast cancer treatment had met its primary goal after demonstrating a 'clinically-meaningful response' in patients with a more aggressive version of the disease and poorer prognosis.

AstraZeneca is the UK's 6th largest company by market capitalisation. The shares currently yield 3.7% gross per annum and dividends are paid in March and September of each year. We hold AstraZeneca as part of your growth & income equity allocation and have a base target price of 7000p.

This stock is typically (but not invariably) held within Income, Balanced, Growth, Adventurous and Bespoke portfolios.

Balkerne Asset Management
1 Balkerne Hill, Colchester, Essex CO3 3FG
Freephone 0808 200 0808

None of the statements or contents contained within this commentary should be taken or considered as advice and past performance is no guarantee of future returns.

Balkerne Asset Management is a trading style of Capel Court Plc which is authorised & regulated by The Financial Conduct Authority; FCA Registered Number 154146